Cycle Pharmaceuticals Extends Tender Offer for Applied Therapeutics…

Event summary

Cycle Pharmaceuticals extended its tender offer for Applied Therapeutics until January 28, 2026.
Approximately 41.29% of Applied Therapeutics' outstanding shares have been validly tendered as of January 27, 2026.
The offer includes $0.088 per share in cash plus one non-tradeable contingent value right per share.
The tender offer is conditioned upon the tender of a majority of Applied Therapeutics' outstanding shares.

The big picture

Cycle Pharmaceuticals' extension of the tender offer for Applied Therapeutics reflects its strategic push into rare disease treatments. The move comes amid broader industry consolidation, as pharmaceutical companies seek to expand their portfolios in specialized therapeutic areas. The success of this acquisition will depend on Cycle's ability to integrate Applied Therapeutics' assets and meet regulatory requirements.

What we're watching

Deal Completion: Whether Cycle Pharmaceuticals can secure a majority of Applied Therapeutics' shares to meet the tender offer conditions.
Strategic Fit: How the acquisition aligns with Cycle Pharmaceuticals' focus on rare disease treatments and its long-term growth strategy.
Market Reaction: The impact of the extended tender offer on Applied Therapeutics' stock price and investor sentiment.